Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Health Research Projects

McGill University

$290,215.00

Acceleration and Intensification of Cell Culture-Produced Influenza Vaccines for Rapid Response to Pandemic Situation

EF 2018-19

Résumé
Over the last decades, significant investments have been directed by the US Department of*Health and other national and international authorities to build capacities and implement*preparedness plans to face influenza pandemic situations. During influenza pandemic,*countries have increased vaccine demand for their own population and it is critical to have*rapid availability of matched vaccines. However, it may be highly problematic to meet the*expected vaccine demand with current egg-based manufacturing process, for instance in the*case of an avian pandemic strain that could potentially disrupt the supply chain of eggs.*Therefore, alternative production processes, including cell culture and plant-based production*platforms using recombinant technology, have been developed and validated following*recommendations from National and International Health authorities to develop alternative*and complementary technologies for rapid and effective responses in emergency situations.*Currently in Canada, influenza vaccine production is carried out by only one manufacturer*using egg-based production technology. Although plant-based process and production*capacities are currently being developed by Medicago, for a solid and sustain preparedness*plan to face influenza potential pandemics and other emerging infectious disease, it is highly*strategic for Canada to invest in cell culture produced viral vaccine capacities as it is the case*in the US. Taking advantages of advanced technologies recently developed in the applicants*laboratories and cell-culture production capacities already operational at Pnuvax Inc., we aim*to accelerate and intensify, by addressing the limitations at all process steps, the*development and validation of a cell-culture production platform for pandemic influenza*vaccines as a national alternative and complementary vaccines source.
Programme
Collaborative Health Research Projects
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
508335-2017
Name nom
Kamen, Amine
Department département
Bioengineering
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2017
Award amount
290215
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
2
Nb partie
3
Application title
Acceleration and Intensification of Cell Culture-Produced Influenza Vaccines for Rapid Response to Pandemic Situation
Keyword
NSERC
Application summary
Over the last decades, significant investments have been directed by the US Department of*Health and other national and international authorities to build capacities and implement*preparedness plans to face influenza pandemic situations. During influenza pandemic,*countries have increased vaccine demand for their own population and it is critical to have*rapid availability of matched vaccines. However, it may be highly problematic to meet the*expected vaccine demand with current egg-based manufacturing process, for instance in the*case of an avian pandemic strain that could potentially disrupt the supply chain of eggs.*Therefore, alternative production processes, including cell culture and plant-based production*platforms using recombinant technology, have been developed and validated following*recommendations from National and International Health authorities to develop alternative*and complementary technologies for rapid and effective responses in emergency situations.*Currently in Canada, influenza vaccine production is carried out by only one manufacturer*using egg-based production technology. Although plant-based process and production*capacities are currently being developed by Medicago, for a solid and sustain preparedness*plan to face influenza potential pandemics and other emerging infectious disease, it is highly*strategic for Canada to invest in cell culture produced viral vaccine capacities as it is the case*in the US. Taking advantages of advanced technologies recently developed in the applicants*laboratories and cell-culture production capacities already operational at Pnuvax Inc., we aim*to accelerate and intensify, by addressing the limitations at all process steps, the*development and validation of a cell-culture production platform for pandemic influenza*vaccines as a national alternative and complementary vaccines source.